Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Mar;77(5):739–744. doi: 10.1038/bjc.1998.121

Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.

M J Campbell 1, M Dawson 1, H P Koeffler 1
PMCID: PMC2149965  PMID: 9514052

Abstract

Hormonally insensitive prostate cancer is a relatively slow-growing, but usually fatal, disease with no long-term treatment options. Transformation of normal prostate cells to a malignant phenotype often involves corruption of the apoptotic machineries. Bcl-2 protein is one of the key inhibitors of apoptosis and is often unregulated in advanced prostate cancer. The prostate cancer cell line DU-145 was used as a model of a hormonally insensitive, advanced prostate cancer. Cell growth in liquid culture was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control sense oligonucleotides; inhibition by these oligonucleotides was significantly enhanced on combination with the synthetic retinoid N-(2-hydroxyphenyl)all-trans-retinamide (2-HPR). Interestingly, growth inhibition occurred in the absence of apoptosis as measured using two assay techniques. We hypothesize that in these recalcitrant cells the apoptotic pathway is compromised at several levels, and Bcl-2 may play another role in promoting cell growth. The use of Bcl-2 antisense oligonucleotides plus 2-HPR may provide a novel approach to therapy of hormone-resistant prostate cancer.

Full text

PDF
739

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apakama I., Robinson M. C., Walter N. M., Charlton R. G., Royds J. A., Fuller C. E., Neal D. E., Hamdy F. C. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 1996 Oct;74(8):1258–1262. doi: 10.1038/bjc.1996.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbareschi M., Caffo O., Veronese S., Leek R. D., Fina P., Fox S., Bonzanini M., Girlando S., Morelli L., Eccher C. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996 Nov;27(11):1149–1155. doi: 10.1016/s0046-8177(96)90307-x. [DOI] [PubMed] [Google Scholar]
  3. Bauer J. J., Sesterhenn I. A., Mostofi F. K., McLeod D. G., Srivastava S., Moul J. W. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996 Oct;156(4):1511–1516. [PubMed] [Google Scholar]
  4. Berchem G. J., Bosseler M., Sugars L. Y., Voeller H. J., Zeitlin S., Gelmann E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 1995 Feb 15;55(4):735–738. [PubMed] [Google Scholar]
  5. Blutt S. E., Allegretto E. A., Pike J. W., Weigel N. L. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997 Apr;138(4):1491–1497. doi: 10.1210/endo.138.4.5063. [DOI] [PubMed] [Google Scholar]
  6. Campos L., Sabido O., Rouault J. P., Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 1994 Jul 15;84(2):595–600. [PubMed] [Google Scholar]
  7. Carroll A. G., Voeller H. J., Sugars L., Gelmann E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993;23(2):123–134. doi: 10.1002/pros.2990230206. [DOI] [PubMed] [Google Scholar]
  8. Chomienne C., Fenaux P., Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J. 1996 Jul;10(9):1025–1030. doi: 10.1096/fasebj.10.9.8801163. [DOI] [PubMed] [Google Scholar]
  9. Danesi R., Figg W. D., Reed E., Myers C. E. Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol. 1995 Jun;47(6):1106–1111. [PubMed] [Google Scholar]
  10. Delia D., Aiello A., Formelli F., Fontanella E., Costa A., Miyashita T., Reed J. C., Pierotti M. A. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood. 1995 Jan 15;85(2):359–367. [PubMed] [Google Scholar]
  11. Feldman D., Skowronski R. J., Peehl D. M. Vitamin D and prostate cancer. Adv Exp Med Biol. 1995;375:53–63. doi: 10.1007/978-1-4899-0949-7_5. [DOI] [PubMed] [Google Scholar]
  12. Gaddipati J. P., McLeod D. G., Heidenberg H. B., Sesterhenn I. A., Finger M. J., Moul J. W., Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994 Jun 1;54(11):2861–2864. [PubMed] [Google Scholar]
  13. Golstein P. Controlling cell death. Science. 1997 Feb 21;275(5303):1081–1082. doi: 10.1126/science.275.5303.1081. [DOI] [PubMed] [Google Scholar]
  14. Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol. 1996;17(6):341–344. doi: 10.1159/000217998. [DOI] [PubMed] [Google Scholar]
  15. Hsieh T. C., Xu W., Chiao J. W. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp Cell Res. 1995 May;218(1):137–143. doi: 10.1006/excr.1995.1140. [DOI] [PubMed] [Google Scholar]
  16. Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567–572. [PubMed] [Google Scholar]
  17. Isaacs W. B., Bova G. S., Morton R. A., Bussemakers M. J., Brooks J. D., Ewing C. M. Genetic alterations in prostate cancer. Cold Spring Harb Symp Quant Biol. 1994;59:653–659. doi: 10.1101/sqb.1994.059.01.075. [DOI] [PubMed] [Google Scholar]
  18. Jacobsen S. J., Katusic S. K., Bergstralh E. J., Oesterling J. E., Ohrt D., Klee G. G., Chute C. G., Lieber M. M. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995 Nov 8;274(18):1445–1449. [PubMed] [Google Scholar]
  19. Kantarjian H. M., Estey E. H., Keating M. A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia. 1996 Apr;10 (Suppl 1):S4–S6. [PubMed] [Google Scholar]
  20. Kazmi S. M., Plante R. K., Visconti V., Lau C. Y. Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res. 1996 Mar 1;56(5):1056–1062. [PubMed] [Google Scholar]
  21. Keith F. J., Bradbury D. A., Zhu Y. M., Russell N. H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia. 1995 Jan;9(1):131–138. [PubMed] [Google Scholar]
  22. Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996 May;148(5):1567–1576. [PMC free article] [PubMed] [Google Scholar]
  23. Li C. J., Wang C., Pardee A. B. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res. 1995 Sep 1;55(17):3712–3715. [PubMed] [Google Scholar]
  24. Li X., Darzynkiewicz Z. Labelling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif. 1995 Nov;28(11):571–579. doi: 10.1111/j.1365-2184.1995.tb00045.x. [DOI] [PubMed] [Google Scholar]
  25. Liu L., Shack S., Stetler-Stevenson W. G., Hudgins W. R., Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J Invest Dermatol. 1994 Sep;103(3):335–340. doi: 10.1111/1523-1747.ep12394874. [DOI] [PubMed] [Google Scholar]
  26. McConkey D. J., Greene G., Pettaway C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res. 1996 Dec 15;56(24):5594–5599. [PubMed] [Google Scholar]
  27. Novichenko N., Konno S., Nakajima Y., Hsieh T. C., Xu W., Turo K., Ahmed T., Chiao J. W. Growth attenuation in a human prostate cell line mediated by a phorbol ester. Proc Soc Exp Biol Med. 1995 Jun;209(2):152–156. doi: 10.3181/00379727-209-43889. [DOI] [PubMed] [Google Scholar]
  28. Paquette R. L., Koeffler H. P. Differentiation therapy. Hematol Oncol Clin North Am. 1992 Jun;6(3):687–706. [PubMed] [Google Scholar]
  29. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1997. CA Cancer J Clin. 1997 Jan-Feb;47(1):5–27. doi: 10.3322/canjclin.47.1.5. [DOI] [PubMed] [Google Scholar]
  30. Peck R., Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer. 1991;27(1):53–57. doi: 10.1016/0277-5379(91)90061-h. [DOI] [PubMed] [Google Scholar]
  31. Pemrick S. M., Lucas D. A., Grippo J. F. The retinoid receptors. Leukemia. 1994;8 (Suppl 3):S1–10. [PubMed] [Google Scholar]
  32. Pienta K. J., Nguyen N. M., Lehr J. E. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res. 1993 Jan 15;53(2):224–226. [PubMed] [Google Scholar]
  33. Planchon S. M., Wuerzberger S., Frydman B., Witiak D. T., Hutson P., Church D. R., Wilding G., Boothman D. A. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 1995 Sep 1;55(17):3706–3711. [PMC free article] [PubMed] [Google Scholar]
  34. Pollard M., Luckert P. H., Sporn M. B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991 Jul 1;51(13):3610–3611. [PubMed] [Google Scholar]
  35. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistoia V., Raffaghello L., Rozzo C., Montaldo P. G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995 Feb 15;55(4):853–861. [PubMed] [Google Scholar]
  36. Raffo A. J., Perlman H., Chen M. W., Day M. L., Streitman J. S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995 Oct 1;55(19):4438–4445. [PubMed] [Google Scholar]
  37. Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J. C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997 Feb 14;275(5302):967–969. doi: 10.1126/science.275.5302.967. [DOI] [PubMed] [Google Scholar]
  38. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 1993 Jul 1;82(1):15–21. [PubMed] [Google Scholar]
  39. Samid D., Shack S., Myers C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993 May;91(5):2288–2295. doi: 10.1172/JCI116457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Saunders D. E., Christensen C., Williams J. R., Wappler N. L., Lawrence W. D., Malone J. M., Malviya V. K., Deppe G. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs. 1995 Aug;6(4):562–569. doi: 10.1097/00001813-199508000-00009. [DOI] [PubMed] [Google Scholar]
  41. Smith M. R., Abubakr Y., Mohammad R., Xie T., Hamdan M., al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther. 1995 Sep;2(3):207–212. [PubMed] [Google Scholar]
  42. Suzuki A., Matsuzawa A., Iguchi T. Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene. 1996 Jul 4;13(1):31–37. [PubMed] [Google Scholar]
  43. Takayama S., Sato T., Krajewski S., Kochel K., Irie S., Millan J. A., Reed J. C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell. 1995 Jan 27;80(2):279–284. doi: 10.1016/0092-8674(95)90410-7. [DOI] [PubMed] [Google Scholar]
  44. Tamimi Y., Bringuier P. P., Smit F., van Bokhoven A., Debruyne F. M., Schalken J. A. p16 mutations/deletions are not frequent events in prostate cancer. Br J Cancer. 1996 Jul;74(1):120–122. doi: 10.1038/bjc.1996.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Trump D. L. Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. Leukemia. 1994;8 (Suppl 3):S50–S54. [PubMed] [Google Scholar]
  46. Wang T. T., Phang J. M. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett. 1996 Oct 1;107(1):65–71. doi: 10.1016/0304-3835(96)04344-3. [DOI] [PubMed] [Google Scholar]
  47. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol. 1994 Nov-Dec;72(11-12):537–545. doi: 10.1139/o94-072. [DOI] [PubMed] [Google Scholar]
  48. Wright A. S., Thomas L. N., Douglas R. C., Lazier C. B., Rittmaster R. S. Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat. J Clin Invest. 1996 Dec 1;98(11):2558–2563. doi: 10.1172/JCI119074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yang E., Korsmeyer S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996 Jul 15;88(2):386–401. [PubMed] [Google Scholar]
  50. Zhai S., Yaar M., Doyle S. M., Gilchrest B. A. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res. 1996 May 1;224(2):335–343. doi: 10.1006/excr.1996.0143. [DOI] [PubMed] [Google Scholar]
  51. Zhang W., Grasso L., McClain C. D., Gambel A. M., Cha Y., Travali S., Deisseroth A. B., Mercer W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 1995 Feb 1;55(3):668–674. [PubMed] [Google Scholar]
  52. de Vos S., Dawson M. I., Holden S., Le T., Wang A., Cho S. K., Chen D. L., Koeffler H. P. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate. 1997 Jul 1;32(2):115–121. doi: 10.1002/(sici)1097-0045(19970701)32:2<115::aid-pros6>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES